Karim Mikhail, B. Pharm., M.S., Acting Director of the Center for Biologics Evaluation and Research (CBER), highlighted the importance of the approval, stating, “Patients experiencing life-threatening bleeding in combat zones, disasters, rural settings, or other austere environments may now have faster access to plasma when conventional frozen plasma is unavailable.”

“This milestone action addresses an important unmet medical need — particularly for our military personnel and others who may be far from traditional hospital infrastructure,” he added.

Developed from a single unit of fresh frozen plasma collected from FDA-licensed blood establishments, Ezplaz is a freeze-dried (lyophilized) plasma product available in Group AB and Group A with low-titer anti-B blood types. These blood groups were selected to reduce the risk of transfusion before a patient’s blood type has been identified during emergencies.

Unlike conventional plasma products that require frozen storage followed by thawing before use, this freeze-dried plasma product can be stored at room temperature, withstand temperature fluctuations, and be rapidly reconstituted when needed. It is supplied in a plastic bag instead of a glass bottle, lowering the possibility of breakage during transportation and handling. According to the FDA, these characteristics make Ezplaz well suited for use in austere environments, including combat zones, remote locations, and disaster response operations.

The product is indicated for adult patients requiring plasma when alternative plasma products are unavailable, including bleeding patients, patients needing massive transfusion, or certain patients on warfarin who are bleeding. Each Ezplaz kit contains one unit of freeze-dried plasma sealed in an outer foil pouch, one 250 mL bag of sterile water for injection, one sterile fluid transfer set, and one sterile blood transfusion set.

FDA Highlights Scientific Review and Military Collaboration Behind Approval

Commenting on the approval, Anne Eder, M.D, Ph.D., Director of the Office of Blood Research and Review (CBER), said, “This licensure demonstrates that innovation and rigorous scientific review can advance together, expanding treatment options and novel blood components while maintaining FDA’s standards for safety, purity, and potency.”

The approval follows efforts initiated under Public Law 115-92, enacted in December 2017, which authorized the DoD (now DoW)-FDA collaboration to help accelerate the development and review of products intended for serious or life-threatening conditions affecting American military personnel. As part of that initiative, the FDA issued guidance in 2019 to support manufacturers developing dried plasma products for transfusion.

After reviewing the available data, the agency concluded that, for the approved uses, the benefits of the freeze-dried plasma product outweigh its risks. The FDA noted that the safety profile of Ezplaz is consistent with other plasma products used for transfusion, while emphasizing that patients and healthcare providers should remain aware of transfusion-related risks and that healthcare providers should review the complete prescribing information before administration. The biologics license for Ezplaz was granted to Vascular Solutions, LLC, a subsidiary of Teleflex.

Under the proposed framework, distributed manufacturing establishments would continue operating with a central quality oversight hub connected to multiple equivalent manufacturing units across different locations. Existing regulations require every manufacturing unit within such a network to complete a separate registration, resulting in administrative complexity. Through the proposed drug manufacturing registration changes, these distributed manufacturing establishments could instead register as a single establishment. The proposal would also allow manufacturing units to be added, relocated or removed using a streamlined update process. In addition, companies would be required to notify the FDA before relocating any manufacturing unit, addressing a gap in the agency’s real-time oversight capabilities.

“The FDA is proposing changes to our establishment registration regulations that would reflect how distributed manufacturing actually works — as one single establishment,” said Michael Davis, M.D., Ph.D., Acting Director of FDA’s Center for Drug Evaluation and Research.

“The proposed changes would make it easier for innovative manufacturers to operate efficiently, and give the FDA a clearer, more accurate picture of how and where drugs are being made,” he added.

Proposal Clarifies Foreign Registration Requirements and Supply Chain Visibility

Beyond domestic manufacturing, the proposed rule also addresses drug manufacturing registration and drug listing obligations for certain foreign drug manufacturing establishments. At present, some foreign establishments that manufacture drugs, including components of drugs such as active pharmaceutical ingredients, exclusively for distribution to other foreign establishments may not be registered with the FDA.

According to the agency, this limits visibility into upstream supply chains. By aligning the regulations with statutory requirements, the proposed rule would make it clear that these establishments are required to register with the FDA and report the drugs they manufacture. The agency says this would improve its ability to identify and respond to potential safety concerns affecting the supply chain.

If the proposed rule is finalized, the FDA expects it to lower registration costs for distributed manufacturing companies while creating long-term efficiencies for both the pharmaceutical industry and the agency. The proposal also builds on a series of administration actions focused on revitalizing American pharmaceutical manufacturing, strengthening supply chain transparency, and reducing vulnerabilities across the drug supply chain.

Concussions remain one of the most prevalent and undertreated neurological injuries worldwide. Despite growing awareness around traumatic brain injury (TBI) in sports, military medicine, and emergency care, treatment options remain limited, with no FDA-approved therapeutic specifically indicated for concussion or mild traumatic brain injury.

This gap has prompted renewed interest in novel CNS drug delivery approaches, particularly those capable of delivering treatment rapidly following the occurrence of an injury. Among the emerging strategies, intranasal administration is gaining momentum as a potentially transformative modality.

An Unmet Need in Neurotrauma

Over 69 million patients globally experience a concussion each year. While most cases are classified as mild traumatic brain injury, the downstream biological consequences can be significant. Patients often experience headaches, dizziness, cognitive impairment, sleep disturbance, and, in some cases, persistent neurological symptoms that can last weeks, months, or years.

Current clinical management remains largely supportive. Patients are evaluated, monitored, and advised on rest and symptom management, but there is no approved intervention to actively reduce the secondary biochemical injury cascade following trauma.

That secondary cascade including oxidative stress, neuroinflammation, excitotoxicity, and mitochondrial dysfunction has become a major focus of neurotrauma research. Because these processes evolve over hours after injury, many researchers view the immediate post-injury period as a critical therapeutic window.

The challenge has been delivering an effective therapeutic quickly enough (and directly enough) to alter that progression.

Why Intranasal Delivery is Drawing Attention

Intranasal delivery has become an increasingly important area of interest across CNS therapeutics because it offers the potential to bypass some of the traditional barriers that have historically limited neurological drug development.

Unlike oral administration, intranasal delivery avoids first-pass metabolism and gastrointestinal degradation. Unlike IV administration, it requires no needles or clinical setup. Most importantly for neurological applications, it may enable more direct access to the central nervous system via the nasal cavity.

For acute indications such as concussions, this creates several practical advantages:

• Rapid administration immediately after injury
• Non-invasive dosing outside hospital settings
• Potentially improved CNS exposure
• Portability for use in sports medicine, military settings, emergency response, or ambulatory care
• Reduced delay between injury and treatment

These attributes align particularly well with concussions, where therapeutic effectiveness may depend heavily on how quickly intervention occurs.

Repurposing Known Molecules for New Neurological Applications

One notable trend across biotech is the repurposing of well-characterized molecules with established safety profiles into novel delivery systems or indications. This approach can reduce development risk while opening new therapeutic applications.

Within this space, Beyond Barriers Therapeutics is developing BBT-101, an intranasal formulation of N-acetylcysteine (NAC) for mild and moderate traumatic brain injury.

NAC has long been recognized for its antioxidant properties and for its role in glutathione replenishment. Its mechanism of reducing oxidative stress makes it particularly relevant in neurological injury, where oxidative damage is a major contributor to secondary tissue injury following trauma.

By pairing NAC with a proprietary intranasal delivery strategy, Beyond Barriers is exploring whether a familiar therapeutic agent can be adapted into a field-ready intervention for acute brain injury.

The company’s development strategy reflects a broader industry movement toward combining established compounds with novel delivery technologies to address unmet needs in CNS care.

A Market Positioned for Innovation

Several healthcare sectors are converging around the need for better concussion treatment.

Sports Medicine

Concussion protocols in professional, collegiate, and youth athletics continue to evolve, but treatment remains limited once injury occurs. As awareness of long-term neurological effects grows, interest in rapid-response therapeutic intervention continues to increase.

Military Medicine

Traumatic brain injury remains one of the most common injuries among active-duty military personnel. Blast exposure and training-related injuries continue to create demand for therapies that can be administered in austere or field-forward environments.

Intranasal therapeutics offer a practical advantage in these settings because they can be delivered without IV access and with minimal equipment.

Emergency and Acute Care

Emergency departments continue to manage large volumes of head trauma annually, yet clinicians lack a pharmacologic intervention specifically designed to mitigate early neurological injury progression following a concussion.

This presents a substantial opportunity for therapeutic innovation in acute care medicine.

Broader Implications for CNS Drug Development

Although concussion may be the initial target, the broader implications of nose-to-brain delivery extend well beyond neurotrauma.

Oxidative stress and neuroinflammation are implicated across multiple neurological disorders, including seizure disorders, strokes, neurodegenerative disease, and cognitive decline.

As a result, successful validation of intranasal CNS delivery platforms could create opportunities across multiple indications.

For biopharma companies, this represents more than a single-product opportunity, instead pointing toward platform potential.

The broader industry has already seen increasing interest in intranasal delivery across seizure rescue medications, migraine therapies, and neuropsychiatric indications. The next phase may be expansion into acute neuroprotection and traumatic injury.

Looking Ahead

Concussion treatment has remained largely unchanged for decades despite growing scientific understanding of brain injury biology.

That may be beginning to shift.

Improved diagnostics, biomarker development, and advances in CNS drug delivery are creating a more favorable environment for therapeutic development than ever before. At the same time, healthcare systems are increasingly prioritizing earlier intervention in neurological injury rather than observation alone.

Intranasal therapeutics sit at the center of that evolution.

Whether in sports medicine, military applications, or emergency care, the ability to deliver a therapeutic at the point of injury (within minutes rather than hours) could fundamentally reshape the treatment paradigm for concussion.

For the broader pharmaceutical industry, Beyond Barriers Therapeutics reflects an emerging category worth watching companies applying novel delivery science to longstanding neurological challenges.

If successful, these efforts may not only change how a concussion is treated, but how acute brain injury is managed altogether.

A 64-week, late-stage study demonstrated that participants who took 25 mg of oral semaglutide once a day went on to lose an average of 16.6% of their body weight, as compared with 2.7% for those on a placebo. The pill was given a nod for chronic weight management within adults with obesity or overweight and a minimum of one related health condition, therefore widening the potential patient pool at a time when the insurers, employers, and governments are battling it out with spiraling healthcare expenses related to obesity. It could also help open the door to tens of millions of untapped patients in an international market, forecast to be somewhere around $150 billion a year by the next decade. As per chief AI officer Anand Iyer at Welldoc, a telehealth firm, there is going to be a huge uptake in the patient base that is about to be seen as new indications open up and as the oral versions hit the market. Novo’s executive vice president of U.S. operations, David Moore, said that a daily pill could also boost the interest and uptake of the drug. Novo is apparently manufacturing the pill in the United States in North Carolina and has been building up supplies of the pill for quite some time now to ensure that it has enough supply.

Around 40% of American adults are obese, as per the U.S. government data, and almost 12% say that they are at present on GLP-1 drugs, as per a poll published in November 2025 by KFF, the health policy research organization. Novo apparently had a first-to-market advantage in terms of injectables; however, it initially struggled to meet that explosive demand. Eventually, Lilly went ahead with its Zepbound, which now goes on to lead when it comes to weekly U.S. prescriptions. Novo, along with analysts, says that a weight-loss pill would very well address the injection hesitancy and hence lead to expansion in access.

According to managing director and partner at BCG, Christopher Chrisman, the pills are not going to displace or replace the injections, adding that some patients may prefer to go ahead with their weekly injections. However, the pills do offer clear benefits to some people. There is indeed a level of travel convenience and no requirement to have a fridge,” he added. Novo remarked that the 1.5-milligram starting dose of the Wegovy pill is going to be available in early January 2026. Novo as well as Lilly had gone on to agree to provide starter doses in terms of their weight-loss pills at $149 for every month for the U.S. government Medicare and Medicaid health insurance programs and also to cash-paying customers through the direct-to-consumer TrumpRx site from the White House.

Novo recently slashed the cash price for Wegovy to $349 per month, from $499. Mike Doustdar, the Novo CEO, said that in November 2025, people making use of the weight-loss drugs showed more consumer-like behavior as compared to its traditional diabetes patients, therefore acknowledging that the company is required to adapt to this and also bring in the new expertise. Whether another semaglutide product can go ahead and solve the current ills of Novo remains to be seen. The weight loss pill from Novo Nordisk, oral semaglutide, has to be taken in the morning on an empty stomach, which is 30 minutes prior to eating, drinking, or using any kind of other oral medication.

According to the Chief Medical Officer and Head of Global Product Development at Roche, Levi Garraway, MD, PhD, since follicular lymphoma often needs lifelong management, decreasing the burden of care for such individuals is indeed of major importance. Due to this FDA approval, treatment can now be administered in about one minute, which prominently decreases the time patients spend within the clinic and helps to sync care along with their individual requirements as well as preferences.

It is well to be noted that VELO decreases the treatment administration time with an approx. one-minute injection as compared with a 2-4 hour intravenous (IV) infusion. Like Lunsumio, which is administered intravenously, Lunsumio VELO by Roche can be administered outpatient and is a fixed-duration treatment that is given for a defined period, and that could be as short as six months. By contrast, treat-to-progression treatment alternatives are designed to be given to patients indefinitely until the time of disease progression or till treatment can no longer be tolerated. Tennessee Oncology and One Oncology’s Dr. Ian Flinn, MD, PhD, says that this approval is a major step when it comes to broadening access to effective treatments for people who are living with follicular lymphoma. Due to its manageable cytokine release syndrome profile as well as decreased administration time, Lunsumio VELO helps oncologists to roll out advanced care across the community practice settings.

Interestingly, the FDA approval has received support from the primary analysis of the GO29781 study, which evaluated Lunsumio VELO across patients having third-line or later (3L+ FL). Inferences showed that the objective response rate as well as the complete response rate within patients treated with Lunsumio VELO were 75% (95% confidence interval [CI]: 64–83%) and 59% (95% CI: 48–69%), respectively. The median duration when it comes to response was 22.4 months – 95% CI: 16.8–22.8. The most common adverse reactions (≥20%) were the injection site reactions, such as fatigue, rash, cytokine release syndrome (CRS), COVID-19 infection, and musculoskeletal pain, as well as diarrhea. Notably, the CRS rate was 30%, and events were mostly low grade, i.e., Grade 1–2 (28%) and Grade 3 (2.1%) occurred in Cycle 1, and all resolved post a median duration of two days (range: 1–15). Apparently, CRS can be severe as well as life-threatening.

It is well to be noted that Lunsumio IV was the first bispecific antibody that was approved for 3L+ FL. Long-term data from the SC as well as IV arms of the GO29781 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition. These data have been submitted to other healthcare authorities throughout the world. Recently, the European Commission went on to grant a conditional marketing authorization of Lunsumio SC when it comes to the treatment of adult patients having R/R FL post two or more lines of systemic therapy.

Roche goes on to advance its bispecific antibody programme within the gamut of lymphoma, with ongoing phase III studies assessing Lunsumio and Lunsumio VELO within the earlier lines of treatment. This goes on to include the SUNMO study, which investigates the Lunsumio VELO in combination with Polivy® (polatuzumab vedotin) in the second-line or later large B-cell lymphoma, as well as the MorningLyte study, which investigates the Lunsumio VELO in combination with lenalidomide in past untreated FL.

The Cytokinetics Myqorzo approval follows a period of volatility for the biotech, which was founded in 1997 and has only now brought its first product to market. The company faced setbacks when a late-stage ALS program failed and another cardiovascular therapy was rejected by regulators, but Myqorzo’s progress reshaped its development outlook.  Like Camzyos, Myqorzo is a cardiac myosin inhibitor that works by relaxing heart muscle contraction to improve cardiac function, and both drugs are approved for the obstructive form of hypertrophic cardiomyopathy. But differences in how the therapies are prescribed could influence how the market develops. Myqorzo carries a heart failure warning similar to Camzyos, while its risk mitigation requirements are less restrictive. RBC Capital Markets analyst Leonid Timashev wrote that Myqorzo’s protocol allows more flexible dose adjustments, less frequent echocardiograms, and minimal drug-interaction monitoring, factors he said “should materially lower barriers to prescribing” compared with Camzyos.

Despite the significance of the Cytokinetics Myqorzo approval, investor reaction was muted, with analysts noting that labeling outcomes largely matched expectations. Stifel analyst James Condulis said there remains “debate” around the “extent” of Myqorzo’s differentiation from Camzyos, even as attention turns to upcoming clinical data. Cytokinetics is expected to report results from a study evaluating Myqorzo in patients with the non-obstructive form of hypertrophic cardiomyopathy, a setting in which Camzyos failed in a Phase 3 trial. Some analysts believe Myqorzo’s broader therapeutic dosing range could offer an advantage, though outcomes remain to be seen. “We’re bullish and expect [Myqorzo] to become the best [and] only drug for the entire HCM spectrum,” Condulis wrote.

Pricing for Myqorzo is expected to be “in line with” Camzyos, according to a company spokesperson, with details to be disclosed ahead of launch. Camzyos entered the market with an annual wholesale acquisition cost of $89,500. Myqorzo has also received regulatory clearance in China, extending its geographic footprint beyond the U.S. market. As Cytokinetics transitions from a development-stage biotech to a commercial drug company, the Cytokinetics Myqorzo FDA approval represents a pivotal step in establishing a long-term presence in cardiovascular therapeutics.

Following the initial dosing phase, patients receive inebilizumab-cdon twice yearly, a schedule designed to simplify long-term management for individuals who may find frequent or complex regimens difficult to maintain. In addition to its newly approved indication for generalized myasthenia gravis, the therapy is also approved for adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and immunoglobulin G4-related disease. Commenting on the decision, Jay Bradner, MD, executive vice president of research and development at Amgen, said in a news release, “This approval marks a significant advancement for people living with gMG. By selectively targeting CD19-positive B cells, [inebilizumab] offers a new approach to treatment that addresses a biological root cause of disease. [Inebilizumab] is conveniently dosed twice a year and delivers durable efficacy, helping people manage debilitating symptoms that can compromise daily function—including trouble breathing, speaking, and seeing.”

The FDA decision on inebilizumab-cdon for generalized myasthenia gravis was supported by findings from MINT (NCT04524273), a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial evaluating efficacy and safety in adults with gMG. The study enrolled 238 patients, including 190 who were AChR-positive and 48 who were MuSK-positive. Participants were randomized to receive intravenous inebilizumab at a dose of 300 mg on days 1 and 15, with an additional dose on day 183 for AChR-positive patients, or a matching placebo. Treatment continued for 52 weeks in AChR-positive participants and 26 weeks in MuSK-positive participants. The primary endpoint assessed change from baseline in the Myasthenia Gravis Activities of Daily Living score at week 26, while a key secondary endpoint measured change in the Quantitative Myasthenia Gravis score over the same period.

Results from the trial showed that patients treated with inebilizumab achieved greater reductions in disease activity than those receiving placebo, supporting the decision as the FDA approves inebilizumab-cdon for generalized myasthenia gravis. Least-squares mean changes in MG-ADL scores were –4.2 with inebilizumab compared with –2.2 for placebo, while QMG scores declined by –4.8 versus –2.3, respectively. Richard J. Nowak, MD, MS, global principal investigator and director of the Myasthenia Gravis Clinic at Yale University, said in the news release, “[Inebilizumab] showed strong efficacy at 26 weeks in both AChR-positive and MuSK+ patients, with AChR+ patients continuing to improve through 52 weeks in MINT.” The most commonly reported adverse events included headache, cough, nasopharyngitis, infusion-related reactions, and urinary tract infections, with no higher incidence of serious adverse events observed. Manufacturers noted the potential risk of infections and possible fetal harm. Responding to the approval, Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America, said the therapy offers durable efficacy and extended treatment-free intervals for people living with gMG.

“These approvals mark a significant milestone for treatment options for patients with uncomplicated urogenital gonorrhea,” said Adam Sherwat, M.D., director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research (CDER). Gonorrhea, caused by the bacterium Neisseria gonorrhoeae (N. gonorrhoeae), is a localized infection of the urethra or cervix that can lead to painful urination, discharge, and swelling, and may progress to infertility if left untreated. As the FDA approves two oral therapies, the agency highlighted the importance of expanding treatment choices as clinical practice has shifted from combination therapy with ceftriaxone and azithromycin to reliance on a single ceftriaxone injection.

Approval of Nuzolvence was supported by a study involving 930 patients with uncomplicated urogenital gonorrhea. Two-thirds of participants received a single 3-gram dose of Nuzolvence dissolved in water, while the remaining patients received standard treatment consisting of a ceftriaxone shot and an azithromycin pill. Bacterial clearance assessed 4 to 8 days after treatment showed cure rates of 91% for Nuzolvence and 96% for standard treatment, demonstrating comparable effectiveness. Blujepa was evaluated in a separate study of 628 patients, where participants received either two 3,000 mg doses taken 10 to 12 hours apart or standard therapy. Clearance rates assessed 4 to 10 days after treatment showed cure rates of 93% for Blujepa and 91% for standard treatment.

The safety results were in line with what is already known about both drugs. The most common adverse events reported with Nuzolvence included low white blood cell counts, headache, dizziness, nausea, and diarrhea, while Blujepa’s most frequently reported side effects included gastrointestinal symptoms, headache, fatigue, excessive sweating, and dizziness, with warnings related to heart rhythm effects, acetylcholinesterase inhibition, and allergic reactions. Both therapies received Fast Track, Qualified Infectious Disease Product, and Priority Review designations. As part of the FDA approval for gonorrhea medications, approval of Nuzolvence was granted to Entasis Therapeutics, while approval for Blujepa was granted to GSK.

The new draft guidance goes on to remove the need for single-target or monospecific antibodies, which need to be tested for six-month toxicity in NHPs such as cynomolgus macaque or rhesus monkeys as well as marmosets.

Rather, antibody developers can go ahead and extrapolate from three-month studies pertaining to non-rodent species such as NHPs, dogs, and also mini-pigs, supplemented by a weight-of-evidence – WoE risk evaluation that’s based upon the data from similar antibodies.

It is worth noting that the eight-page document notes that, unlike the small-molecule drugs, antibodies are not metabolized by way of biotransformation in the liver; hence, they do not carry the same risk of generating the potentially toxic metabolites.

The guidance does not go on to apply to multispecific antibodies, antibody-drug conjugates, or even drugs based on antibody fragments, as per the FDA.

Earlier in 2025, the regulator remarked that it intends to decrease or replace animal testing of numerous medicines, including the likes of antibodies, with certain other methods that it hopes are going to be more relevant when it comes to human physiology.

Among the other options that are under consideration are artificial intelligence – AI and computational methods, which could as well forecast safety in silico, and human cell lines as well as organoids, which apparently are organ-like structures that are made from human cells as well as tissues, which could as well serve as lab models.

There are similar efforts that are being put forth so as to decrease animal testing of new medicines, and these have also been announced by the EU as well as the UK in recent times.

As per the FDA Commissioner, Marty Makary, they are delivering on their roadmap commitment in order to eliminate animal testing needs in drug assessment and their promise to speed up cures and meaningful treatments for Americans.

He further said that modern science has given a far more effective as well as humane way of assessing drug safety than going ahead with animal testing. He added that this reform may go on to decrease the amount of time it takes to get a drug to the market and lower the research and development expenditures, which can lead to much lower drug prices.

Notably, the FDA also estimates that a typical non-clinical programme having a monoclonal antibody product could also include over 100 NHPs, incurring costs of around $50,000 per animal. But many products that clear toxicity testing within animals do not get the FDA approval, majorly because of safety or efficacy challenges within humans.

Richard Pazdur, who may be retiring from the position of director of the Center for Drug Evaluation and Research of the FDA just a few weeks after starting the job, remarked that knowledge-based risk evaluation of toxicity goes on to reflect scientific progress along with their responsibility to make use of the most effective tools when it comes to drug evaluation.

Congenital heart defects remain one of the most common abnormalities detected at birth, and about 1 in 500 newborns is classified as having a severe condition that requires urgent intervention, according to the National Institutes of Health. Carnegie Imaging for Women, an OB/GYN imaging facility affiliated with Mount Sinai, is the first center in New York City to adopt the FDA-cleared software developed by BrightHeart. The technology is now in use across the group’s three Manhattan locations, where clinicians are applying AI to improve the accuracy and efficiency of ultrasound evaluations at scale.

The study examined 200 deidentified fetal ultrasound examinations conducted between 18 and 24 weeks of gestation across 11 medical centers in two countries. Of these, 100 scans contained at least one suspicious finding. Seven obstetrician-gynecologists and seven maternal-fetal medicine specialists independently reviewed each examination, both with and without the AI tool, to assess whether the technology improved the detection of findings suspicious for severe congenital heart defects. The researchers found that AI assistance was associated with stronger detection of lesions, higher confidence scores, an 18 percent reduction in reading time, and a 19 percent improvement in confidence score, reinforcing the potential of AI-assisted fetal screening in second-trimester ultrasonography.

“AI assistance in prenatal diagnosis offers not only improved detection, but has the potential to offer significant improvement in workflow and efficiency benefits,” said corresponding author Jennifer Lam-Rachlin, MD, Assistant Clinical Professor of Obstetrics, Gynecology and Reproductive Science at the Icahn School of Medicine at Mount Sinai. “We, as clinicians, should embrace innovation and technology that is available, in order to maximize quality patient care. This technology allows for ‘leveling’ of the field of prenatal diagnosis to offer close to expert-level review of fetal ultrasounds, particularly in centers or geographical locations without fetal heart experts.”

Co-author Andrei Rebarber, MD, Director of the Division of Maternal-Fetal Medicine at Mount Sinai West, added that the findings “should prompt and encourage future research into AI-assisted software’s ability to improve detection rates, once integrated into clinical workflows, to reduce the variability and inequity of detection of congenital heart defects globally.”

BrightHeart funded the study, which brought together researchers from multiple U.S. and international institutions, including the Division of Pediatric Cardiology at the Icahn School of Medicine at Mount Sinai; New York University School of Medicine; Maternal Fetal Medicine Associates in New York City; Pediatrics – Cardiology at Stanford University School of Medicine; Palo Alto Medical Foundation, Sutter Health; the Fetal Diagnostic Center of Pasadena; Université Grenoble Alpes and CHU Grenoble Alpes in France; Medical Training Center in Rouen; Centre d’Echographie de l’Odéon and UE3C-Unité d’Explorations Cardiologiques-Cardiopathies Congénitales in Paris; Hôpital Necker-Enfants Maladies in Paris; Michigan Perinatal Associates, Corewell Health East; Wayne State University School of Medicine; Fetal Echocardiography and Perinatal Research–Valley Health System; the Division of Maternal Fetal Medicine at Pennsylvania Hospital, University of Pennsylvania; and Maternal Fetal Medicine, Perinatal Specialists of the Palm Beaches in Florida. Their collective work underscores the growing role of AI-assisted fetal screening as clinicians look to improve prenatal detection and care.